J Thorac Cardiovasc Surg 2004, 127: 1579–1586.CrossRefPubMed 12. Zafirellis K, Agrogiannis G, Zachaki A, Proteases inhibitor Gravani K, Karameris A, Kombouras C: Prognostic Significance of VEGF Expression Evaluated by Quantitative Immunohistochemical Analysis in Colorectal Cancer. J Surg Res 2008, 147: 99–107.CrossRefPubMed 13. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu AG-120 cost K: VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 2005, 8: 155–163.CrossRefPubMed
14. Yilmaz A, Ernam D, Unsal E, Demirag F, Atikcan Ş, Taştepe I: Vascular Endothelial Growth Factor Immunostaining Correlates with Postoperative Relapse and Survival in Non-Small Cell Lung Cancer. Arch Med Res 2007, 38: 764–768.CrossRefPubMed
15. Du JR, Jiang Y, Zhang YM, Fu H: Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinoma. World J Gastroenterol 2003, 9: 1604–1606.PubMed 16. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349: 427–434.CrossRefPubMed 17. Hurwitz H, Fehrenbacher L, check details Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavanr F: Bevacizumab plus irinotecan, fluorouracil, before and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335–2342.CrossRefPubMed 18. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine
kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23: 2544–2555.CrossRefPubMed 19. Fukuzawa M, Sugiura H, Koshinaga, Tatsuo S: Expression of Vascular Endothelial Growth Factor and Its Receptor Flk-1 in Human Neuroblastoma Using In Situ Hybridization. J Pediatr Surg 2002, 37: 1747–1750.CrossRefPubMed 20. Rössler J, Breit S, Havers W, Schweigerer L: Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia. Int J Cancer 1999, 81: 113–117.CrossRefPubMed 21. Ootsuka S, Asami S, Sasaki T, Yoshida Y, Nemoto N, Shichino H, Chin M, Hideo Mugishima H, Suzuki T: Analyses of Novel Prognostic Factors in Neuroblastoma Patients. Biol Pharm Bull 2007, 30: 2294–2299.CrossRefPubMed 22. Ribatti D, Marimpietri D, Pastorino F, Brignole C, Nico B, Vacca A, Ponzoni M: Angiogenesis in Neuroblastoma.